NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Arcutis reported financial results for the fourth quarter and full year 2021 and provided a business update.
Arcutis Biotherapeutics reported a net loss of $71.3 million for Q4 2021, with cash, cash equivalents, and marketable securities totaling $388.6 million. The company believes its financial resources will fund operations into 2024.
- FDA accepted the New Drug Application (NDA) for roflumilast cream for plaque psoriasis in adults and adolescents.
- Enrollment completed for the pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis.
- Pivotal Phase 3 trials are ongoing for roflumilast cream in atopic dermatitis and roflumilast foam in scalp and body psoriasis.
- Secured $225 million in non-dilutive debt financing, extending cash runway into 2024.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$105M
Forward guidance
Arcutis anticipates multiple Phase 3 clinical data readouts and prepares for potential product launch in 2022.
Tailwinds
- Topline data from INTEGUMENT-1 and INTEGUMENT-2 are anticipated by the end of 2022.
- Company intends to submit a supplemental New Drug Application (sNDA) for topical roflumilast cream for the treatment of atopic dermatitis patients aged six years or older in 2023 based on the results of INTEGUMENT-1 and -2.
- Topline data from pivotal Phase 3 trial for the treatment of seborrheic dermatitis is anticipated in mid-year 2022.
- Company expects the data to be sufficient basis for an NDA submission in the first half of 2023.
- Topline data from pivotal Phase 3 trial for the treatment of scalp and body psoriasis is anticipated in the second half of 2022.
Headwinds
- Topline data from INTEGUMENT-PED in 2023.
- Company intends to submit a subsequent sNDA for the younger age cohort based on INTEGUMENT-PED following the potential initial atopic dermatitis approval in patients aged six years or older.
- Risks inherent in the clinical development process and regulatory approval process.
- Timing of regulatory filings.
- Timing and expenses of commercialization efforts.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro